Effect of anti-TNF-α on laser-induced choroidal neovascularization

Chinese Journal of Ophthalmology

Volumn 44, Issue 3, 2008, Pages 200-206

  Shi, Xuan ^a   Semkova, Irina ^a   Kociok, Norbert ^a   Gavranic, Claudia ^a   Becker, Martina ^a   Joussen, Antonia M ^a   Kirchhof, Bernd ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Antibodies, monoclonal; Choroidal neovascularization; Immunoglobulin G; Photic stimulation; Receptor, tumor necrosis factor; Tumor necrosis factor alpha

Indexed keywords

ENALAPRIL; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; C57BL MOUSE; DRUG ANTAGONISM; FEMALE; LASER COAGULATION; METABOLISM; MOUSE; SUBRETINAL NEOVASCULARIZATION; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; ENALAPRIL; FEMALE; LASER COAGULATION; MICE; MICE, INBRED C57BL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57649120976     PISSN: 04124081     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Tsutsumi C, Sonoda K, Egashira K, et al. The critical role of ocuar-infiltration macrophages in the development of choroidal neovascularization. J Leukoc Biol, 2003, 74:25-32.
2. Tsutsumi-miyahara C, Sonoda KH, Egashira K, et al. The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation. Br J Ophthalmol, 2004, 88:1217-1222.
3. Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications, 2001, 15:257-259.
4. Sakurai E, Anand A, Ambati BK, et al. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci, 2003,44:3578-3585.
5. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci, 1999, 40:1891-1898.
6. Cousins SW, Espinosa-Heidmann DG, Csaky KC, et al. Monocyte activation in patients with age-related macular degeneration. A biomarker of risk for choroidal neovascularization? Arch Ophthalmol, 2004, 122:1013-1018.
7. Tartaglia LA, Weber RF, Figari IS, et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA, 1991,88:9292-9296.
8. Koizumi K, Poulaki V, Doebmen S, et al. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci, 2003, 44:2184-2191.
9. Giraudo E, Primo L, Audero E, et al. Tumor necrosis factor alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem, 1998,273:22128-22135.
10. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol, 1997,17: 4015-4023.
11. Yoshida S, Yoshida A, Ishibashi T. Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation. Graefes Arch Clin Exp Oplithalmol, 2004, 242:409-413.
12. Kobayashi Y, Fukuta M, Suzuki M, et al. Inhibitory effect of nifedipine on tumor necrosis factor alpha-induced neovascularization in cultured choroidal explants of streptozotocin-diabetic rat. Biol Pharm Bull, 2005, 28: 242-246.
13. Gardiner TA, Gibson DS, De Gooyer TE. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy, Am J Pathol, 2005, 166: 637-644.
14. Bremman FM, Chantry D, Jackson AM, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet, 1989, 2: 244-247.
15. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J, 2002, 16:438-440.
16. Koizumi K, Poulaki V, Doehmen S, et al. Contribution of TNF-alpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci, 2003, 44: 2184-2191.
17. Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol, 1993, 151:6602-6607.
18. Benitez-del-Castillo JM, Maztinez-de-la-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye, 2005, 19:841-845.
19. Giansanti F, Barbera ML, Virgili G, et al. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Beheet disease. Eur J Ophthalmol, 2004, 14:445-448.
20. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol, 2005,139:537-540.
21. Sakurai E, Anand A, Ambati BK, et al. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci, 2003, 44:3578-3585.
22. Maini RN, Taylor PC, Paleolog E, et al. Anti-tumor necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dig, 1999, 58 Suppl 1:156-160.
23. Hehlgans T, Stoelcker B, Stopfer P, et al. Lymphotoxin-ßreceptor immune interaction promotes tumor growth by inducing angiogenesis. Cancer Res, 2002, 62: 4034-4040.
24. Tsuruoka N, Sugiyama M, Tawaragi Y, et al. Inhibition of in vitro angiogenesis by lymphotoxin and interferon-gamma. Biochem Biophys Res Commum, 1988, 155:429-435.